← Natera overview

Natera vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Natera Inc (NTRA)

Q3 2026
▲3▼1

Natera's Signatera Gains EU Access, Record Revenue, Analyst Upgrades

  • EU IVDR Class C Certification Signatera received EU IVDR Class C certification, ensuring Natera can keep selling the test in Europe beyond 2028. This removes a major regulatory risk and secures a key market for future growth.

    New regulatory approval that secures European market access, a key positive for future revenue.

  • Record Q2 Revenue and Raised Guidance Natera reported record Q2 revenue of $753 million, up 38% from a year ago, and raised its full-year 2026 revenue guidance to $2.85–2.91 billion. Gross margins improved to 65%, showing better profitability.

    Strong financial results and increased outlook directly boost investor confidence and stock price.

  • Signatera Expansion and Analyst Upgrades Signatera expanded into new clinical trials (Angiex, AFT-70 NAVIGATE) and Natera presented the largest lung cancer MRD dataset, supporting adoption. Analysts raised fair value to $344.33, with UBS initiating at Buy and a $435 target.

    New trial partnerships and analyst upgrades signal growing adoption and future revenue potential.

  • Valuation and Insider Selling Risks Despite strong momentum, Natera's stock trades at 16 times sales, insiders are selling shares, and the company remains unprofitable. These factors could limit further upside and add volatility.

    High valuation and insider selling are real counterweights that could cap stock gains.

August 2026
▲4

Natera's Signatera Momentum Builds as Analysts Raise Targets

  • Signatera Expands into New Clinical Trials Natera's Signatera test is being used in two new clinical trials: Angiex's Phase 1 solid tumor study and the AFT-70 NAVIGATE Phase III breast cancer trial. More trial use builds evidence and familiarity, which can lead to more doctors ordering the test and higher future revenue.

    New trial partnerships directly expand Signatera's clinical footprint and support future demand.

  • Largest Lung Cancer MRD Dataset Reinforces Signatera Natera presented the largest lung cancer MRD dataset at a major conference, showing Signatera strongly predicts recurrence and survival. Strong clinical evidence supports broader adoption and payer coverage, which can drive test volume and revenue growth.

    New clinical data strengthens the case for Signatera in lung cancer, a key growth area.

  • Analysts Raise Fair Value on Signatera Execution Analysts lifted Natera's fair value to $344.33 from $282.14, citing Signatera execution and updated forecasts. Multiple firms raised targets, with UBS starting coverage at Buy and a $435 target. Higher targets can attract investors and support the stock price.

    Analyst upgrades and higher price targets directly influence investor sentiment and valuation.

  • Strong Test Volume and Margin Improvement Natera processed over one million tests in a quarter for the first time, with revenue up 38.8%. Margins and free cash flow improved, showing the business is scaling profitably. This operational strength supports the stock's valuation and growth story.

    Record test volume and improving financials demonstrate fundamental business momentum.

Latest
▲4

Natera's Signatera Momentum Builds as Analysts Raise Targets

  • Signatera Expands into New Clinical Trials Natera's Signatera test is being used in two new clinical trials: Angiex's Phase 1 solid tumor study and the AFT-70 NAVIGATE Phase III breast cancer trial. More trial use builds evidence and familiarity, which can lead to more doctors ordering the test and higher future revenue.

    New trial partnerships directly expand Signatera's clinical footprint and support future demand.

  • Largest Lung Cancer MRD Dataset Reinforces Signatera Natera presented the largest lung cancer MRD dataset at a major conference, showing Signatera strongly predicts recurrence and survival. Strong clinical evidence supports broader adoption and payer coverage, which can drive test volume and revenue growth.

    New clinical data strengthens the case for Signatera in lung cancer, a key growth area.

  • Analysts Raise Fair Value on Signatera Execution Analysts lifted Natera's fair value to $344.33 from $282.14, citing Signatera execution and updated forecasts. Multiple firms raised targets, with UBS starting coverage at Buy and a $435 target. Higher targets can attract investors and support the stock price.

    Analyst upgrades and higher price targets directly influence investor sentiment and valuation.

  • Strong Test Volume and Margin Improvement Natera processed over one million tests in a quarter for the first time, with revenue up 38.8%. Margins and free cash flow improved, showing the business is scaling profitably. This operational strength supports the stock's valuation and growth story.

    Record test volume and improving financials demonstrate fundamental business momentum.

July 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Q2 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

June 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

Agilent Technologies Inc (A)

Q3 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

August 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

Latest
▲4

Agilent's Q3 beat and China/reshoring momentum drive shares higher

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with non-GAAP EPS up 18% and raised full-year guidance, sending shares up 9.6% since the report. Broad demand across pharma and China, plus Advanced Therapeutics up nearly 30%, shows the core business is accelerating and supports a higher stock price.

    This is the biggest new positive catalyst this period, directly driving the stock higher.

  • China strength and reshoring orders Management said China delivered double-digit growth in pharma and food and high-teens in advanced materials, and Agilent booked its first reshoring orders from five top-10 pharma companies. This opens a new demand source and supports long-term growth, pushing the stock up.

    New geographic and reshoring demand drivers that were not previously reported and directly boost growth outlook.

  • Instrument replacement cycle and lab automation Agilent is less than halfway through its liquid chromatography replacement cycle, worth 200-300 basis points of growth, and about a quarter through gas chromatography, worth 100 basis points. These multi-year upgrades plus lab automation provide a steady tailwind for revenue and the stock.

    New details on replacement cycles and automation that underpin future growth, not previously reported.

  • New AI product launches and investment Agilent launched a Gen5 AI cell identification module for BioTek imagers and led a multimillion-dollar investment in HALO X-ray Technologies. These moves expand its AI and security screening offerings, signaling innovation that can drive future sales and support the stock.

    New product and investment news that shows Agilent is advancing technology, a positive for future growth.

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.